Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Garadacimab by CSL for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency): Likelihood of Approval
Garadacimab is under clinical development by CSL and currently in Pre-Registration for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency)....
Data Insights
Garadacimab by CSL for Idiopathic Pulmonary Fibrosis: Likelihood of Approval
Garadacimab is under clinical development by CSL and currently in Phase II for Idiopathic Pulmonary Fibrosis. According to GlobalData, Phase...